A Comparison of the Renal Cell Carcinoma Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy –Kidney Symptom Index (FKSI)
Explore this paper's citation graph
Summary
The development of the revised FKSI scale (FKSI-19) is described and its use with the RCC-SI is reconciled and it is found that the FKSI-19 and the RCC-SI addressed similar symptom.
- Type
- article
- Published
- 2009-04-08
- Cited by
- 43
- References
- 30
- Access
- Open access
- OpenAlex
- https://openalex.org/W2095112820
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:5319791
Keywords
Medicine, Kidney cancer, Renal cell carcinoma, Cancer, Cronbach's alpha
References
- Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
- Are inflammatory cytokines the common link between cancer-associated cachexia and depression?
- Data Management and Analysis Methods
- Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy.
- Data management and analysis methods.
- Oncologists' recognition of depression in their patients with cancer.
- Development and validation of a scale to measure disease-related symptoms of kidney cancer.
- Effects of Sorafenib on Symptoms and Quality of Life: Results From a Large Randomized Placebo-Controlled Study in Renal Cancer
- Anxiety and depression in hospitalized patients with cancer: agreement in patient-staff dyads.
- Metaanalysis of the correlation between radiographic tumor response and patient‐reported outcomes
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide
- Assessing Tumor-Related Signs and Symptoms to Support Cancer Drug Approval
- 864 CYSTOCELE REPAIR WITH OR WITHOUT PELVICOL IMPLANT: A TWO YEARS FOLLOW-UP
- Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?
- Quality-of-life evaluation: when do terminal cancer patients and health-care providers agree?
- Handbook of Qualitative Research
- PCN75 AN UPDATED GEOGRAPHIC SUBPOPULATION ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) ENROLLED IN A PHASE III TRIAL OF SUNITINIB VERSUS INTERFERON-ALFA
- 861 EFFECTS OF SUNITINIB VERSUS INTERFERON-ALFA IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS FROM A RANDOMIZED MULTINATIONAL PHASE III TRIAL
- Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system.
- Symptom burden: multiple symptoms and their impact as patient-reported outcomes.
Cited by
- General Population Norms for the Functional Assessment of Cancer Therapy – Kidney Symptom Index (FKSI)
- Development and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancer
- Neue Medikamente in der Onkologie: Nutzen, Risiken und Herausforderungen
- Quality of life in patients with metastatic renal cell carcinoma: Assessment of long-term survivors
- Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
- Development of a disease-specific health-related quality of life (HRQoL) questionnaire intended to be used in conjunction with the general European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) in renal cell carcinoma patients
- Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
- Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma
- Pazopanib in the treatment of advanced renal cell carcinoma
- Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer
- Patient-reported outcome measures in urology
- Important Group Differences on the Functional Assessment of Cancer Therapy–Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) in Patients with Metastatic Renal Cell Carcinoma
- Validity and Usefulness of a Single-Item Measure of Patient-Reported Bother From Side Effects of Cancer Therapy
- Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- Cancer symptom response as an oncology clinical trial end point
- Radium-223 dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
- Quality of life outcomes in patients with localised renal cancer: a literature review
- Ruxolitinib Therapy Followed by Reduced Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis – Myeloproliferative Disorders Research Consortium 114 study
- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
Related papers
- An R Function for Cronbach’s Alpha Analysis: A Case-Based Approach
- Robust estimation of Cronbach's alpha
- Just how reliable is your internal reliability? An overview of Cronbach’s alpha (α)
- SAS and SPSS macros to calculate standardized Cronbach’s alpha using the upper bound of the phi coefficient for dichotomous items
- Phase II Study of Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
- The frequence of renal cell carcinoma in population of patients with kidney tumors.
- Coefficient alpha: conceptualizations and anomalies.
- Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up